Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Galvus, Zomelis
Vildagliptin is an oral anti-diabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor class used for the treatment of type 2 diabetes. It works by increasing incretin levels (GLP-1 and GIP), which stimulate insulin secretion and decrease glucagon secretion, thereby improving glycemic control.
For the treatment of type 2 diabetes mellitus.
Outcome:
Increased risk of hypoglycemia or hyperglycemia
Mechanism:
Alcohol can interfere with vildagliptin's metabolism and glucose regulation.
Outcome:
Potential for fluid retention
Mechanism:
Additive effects on fluid balance.
Outcome:
May mask symptoms of hypoglycemia
Mechanism:
Beta-blockers can mask the adrenergic symptoms of hypoglycemia.
Most likely new formulation: extended-release formulation to improve patient compliance (Year: 2026, 60% confidence).
Based on historical usage patterns and current clinical trial activity, there is a low ( <5%) likelihood of vildagliptin being withdrawn from the market in the next 5 years.
Antidiabetic, DPP-4 Inhibitor
Cyanopyrrolidine